A systematic review of CQ-resistant Plasmodium vivax malaria infections in India.

IF 4.9 4区医学 Q1 PARASITOLOGY

Pathogens and Global Health Pub Date : 2024-06-01 Epub Date: 2023-11-23 DOI:10.1080/20477724.2023.2285179

Vishnu Teja Nallapati, Nitin Gupta, Manjunath H Hande, Kavitha Saravu

{"title":"A systematic review of CQ-resistant Plasmodium vivax malaria infections in India.","authors":"Vishnu Teja Nallapati, Nitin Gupta, Manjunath H Hande, Kavitha Saravu","doi":"10.1080/20477724.2023.2285179","DOIUrl":null,"url":null,"abstract":"Introduction: Chloroquine (CQ) is the drug of choice for treating uncomplicated Plasmodium vivax (P. vivax) malaria in India. The knowledge about the exact burden of CQ resistance in P. vivax in India is scarce. Therefore, this systematic review aimed to assess the prevalence of CQ resistance in reported P. vivax cases from India.Methods: PubMed, EMBASE, and Web of Science, were searched using the search string: 'Malaria AND vivax AND chloroquine AND (resistance OR resistant) AND India'. We systematically reviewed in-vivo and in-vitro drug efficacy studies that investigated the CQ efficacy of P. vivax malaria between January 1995 and December 2022. Those studies where patients were followed up for at least 28 days after initiation of treatment were included.Results: We identified 12 eligible CQ therapeutic efficacy studies involving 2470 patients, Of these 2329 patients were assessed by in-vivo therapeutic efficacy methods and the remaining 141 were assessed by in-vitro methods. CQ resistance was found in 25/1787 (1.39%) patients from in-vivo and in 11/141 (7.8%) patients from in-vitro drug efficacy studies.Conclusion: Based on the available studies, the prevalence of CQ resistance in P. vivax was found to be relatively lower in India. However, continued surveillance and monitoring are crucial to identify the emergence of CQ resistance.","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":" ","pages":"295-304"},"PeriodicalIF":4.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234910/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/20477724.2023.2285179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Chloroquine (CQ) is the drug of choice for treating uncomplicated Plasmodium vivax (P. vivax) malaria in India. The knowledge about the exact burden of CQ resistance in P. vivax in India is scarce. Therefore, this systematic review aimed to assess the prevalence of CQ resistance in reported P. vivax cases from India.

Methods: PubMed, EMBASE, and Web of Science, were searched using the search string: 'Malaria AND vivax AND chloroquine AND (resistance OR resistant) AND India'. We systematically reviewed in-vivo and in-vitro drug efficacy studies that investigated the CQ efficacy of P. vivax malaria between January 1995 and December 2022. Those studies where patients were followed up for at least 28 days after initiation of treatment were included.

Results: We identified 12 eligible CQ therapeutic efficacy studies involving 2470 patients, Of these 2329 patients were assessed by in-vivo therapeutic efficacy methods and the remaining 141 were assessed by in-vitro methods. CQ resistance was found in 25/1787 (1.39%) patients from in-vivo and in 11/141 (7.8%) patients from in-vitro drug efficacy studies.

Conclusion: Based on the available studies, the prevalence of CQ resistance in P. vivax was found to be relatively lower in India. However, continued surveillance and monitoring are crucial to identify the emergence of CQ resistance.

查看原文本刊更多论文

印度抗cq间日疟原虫疟疾感染的系统综述。

简介:氯喹(CQ)是印度治疗无并发症间日疟原虫疟疾的首选药物。关于印度间日疟原虫CQ耐药性的确切负担的知识很少。因此，本系统综述旨在评估印度间日疟报告病例中CQ耐药的流行情况。方法:使用检索词“疟疾、间日疟、氯喹和(耐药或耐药)和印度”对PubMed、EMBASE和Web of Science进行检索。我们系统地回顾了1995年1月至2022年12月期间研究间日疟原虫疟疾CQ疗效的体内和体外药物疗效研究。那些患者在治疗开始后至少随访28天的研究被包括在内。结果:我们纳入了12项符合条件的CQ疗效研究，涉及2470例患者，其中2329例采用体内疗效法评估，141例采用体外疗效法评估。在体内和体外药物疗效研究中，分别有25/1787(1.39%)和11/141(7.8%)患者发现CQ耐药。结论:根据已有的研究，间日疟CQ耐药率在印度相对较低。然而，持续的监测和监测对于确定CQ耐药性的出现至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathogens and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-PARASITOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Pathogens and Global Health is a journal of infectious disease and public health that focuses on the translation of molecular, immunological, genomics and epidemiological knowledge into control measures for global health threat. The journal publishes original innovative research papers, reviews articles and interviews policy makers and opinion leaders on health subjects of international relevance. It provides a forum for scientific, ethical and political discussion of new innovative solutions for controlling and eradicating infectious diseases, with particular emphasis on those diseases affecting the poorest regions of the world.